Coming October 29: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

Precigen at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Precigen brings 2 presentations to SITC 2026 in Phoenix. Its program centres on zopapogene imadenovec-drba, an adenovector-based immunotherapy for recurrent respiratory papillomatosis. It reports complete and lasting responses in patients and looks at retreatment and whether the viral vector is shed from the body.

Organization	SITC 2026 Attendance
Precigen Germantown, MD
precigen.com Biotech A biotechnology company developing gene and cell therapies, including immunotherapies.	Poster Fri Nov 6 12:15–1:45pm 5:30–7pm Open-label study of zopapogene imadenovec-drba retreatment and vector shedding evaluation in adult patients with recurrent respiratory papillomatosis Exhibition Halls 4-6 · Poster 525 Vaccines · Clinical Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm Zopapogene imadenovec-drba, a novel adenovector-based immunotherapy, induces complete and durable responses in recurrent respiratory papillomatosis Exhibition Halls 4-6 · Poster 524 Vaccines · Clinical

Organization

SITC 2026 Attendance

Precigen

Germantown, MD

precigen.com

Biotech

A biotechnology company developing gene and cell therapies, including immunotherapies.

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

Open-label study of zopapogene imadenovec-drba retreatment and vector shedding evaluation in adult patients with recurrent respiratory papillomatosis

Exhibition Halls 4-6 · Poster 525

Vaccines · Clinical